Skip to main content
. 2016 Oct 5;11(10):e0164238. doi: 10.1371/journal.pone.0164238

Table 3. Clinical information of trials using CAG regimen in this study.

Study Patients (NO.) Type of Disease Median age (range) Cytarabine dosage Aclacinomycin dosage CR (%)
Li[78] 12 MDS 53 (40–76) 10mg/m2/12h×14d 14mg/m2/d×4d 50
Su[68] 52 AML (Elderly) NR 10mg/m2/12h×14d 10-14mg/m2/d×4d 73.08
Li[65] 22 AML (Elderly) 68 (61–79) 10mg/m2/12h×14d 10-14mg/m2/d×4d 54.55
Li[47] 18 AML (R/R) 38 (19–65) 10mg/m2/12h×14d 5-7mg/m2/d×8d 72.22
Chen[39] 34 AML (ND & Elderly) 69.5 (60–85) 10mg/m2/12h×14d 14mg/m2/d×8d 67.65
Wei[36] 20 AML (R/R) 38 (12–66) 10mg/m2/12h×14-28d 20mg/d×4d 75
Yi[48] 24 AML NR (54–79) 10mg/m2/12h×14d 10mg/m2/d×7d 25
Su[74] 33 MDS/t-AML 60 (28–77) 25mg/d×14d 10mg/d×8d 42.42
Long[70] 20 AML (Elderly) 70 (60–81) 25mg/m2/12h×14d 9mg/m2/d×7d 65
Zhan[50] 21 AML (Elderly) 68 (60–77) 10mg/m2/12h×14d 14mg/m2/d×4d 66.67

Abbreviations: CR = Complete response; ND = newly diagnosed; R/R = relapsed/refractory; NR = not reported.